Stay Up to Date
Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
April 3, 2023
What’s New with the DTRF Together We Will Weekend?
Read More about What’s New with the DTRF Together We Will Weekend?
March 7, 2023
DTRF Announces The First Publicly Available Desmoid Tumor Immortal Cell Line
Read More about DTRF Announces The First Publicly Available Desmoid Tumor Immortal Cell Line
February 27, 2023
Update: Springworks Therapeutics Has Announced FDA acceptance And Priority Review Of The New Drug Application For Nirogacestat
Clinical Trials December 27, 2022
Breaking News: Springworks Therapeutics Announces Submission Of New Drug Application For Nirogacestat To The U.S. FDA
November 22, 2022
Desmoid Tumors In The Spotlight At The 2022 Connective Tissue Oncology Society (CTOS) Conference
October 27, 2022
DTRF And PeerView Offer CME Accredited Course At CTOS On Treatment Of Desmoid Tumors
Read More about DTRF And PeerView Offer CME Accredited Course At CTOS On Treatment Of Desmoid Tumors
